Select Page

The current disparity in number of biotech start-ups and availability of venture capital in developed nations creates opportunities for emerging market players

A recent paper in Nature Biotechnology (Huggett, 2013) suggests some worrying trends in VC funding in the biotech sector, and a negative impact on start-up financing in the drug and medical device industry in particular. VC financing appears to be at an 8-year low in...